Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7533.091 | 0.9812 | 0.9504 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7533.091 | 1.0685 | 1.1836 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7533.091 | 0.9707 | 0.9228 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7533.091 | 0.6222 | 0.0665 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7533.091 | 0.0081 | -0.9966 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7533.091 | 0.0044 | -0.9985 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7534.091 | 1.0343 | 1.0693 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7534.091 | 0.9956 | 0.9911 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7534.091 | 1.0255 | 1.0515 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7534.091 | 0.9989 | 0.9978 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7534.091 | 1.0966 | 1.1954 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7534.091 | 0.9254 | 0.8493 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7534.091 | 0.4148 | -0.1778 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7534.091 | 0.0016 | -0.9970 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7534.091 | 0.0004 | -0.9993 | 0.9898 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7535.092 | 0.9223 | 0.8614 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7535.092 | 0.9028 | 0.8266 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7535.092 | 0.8857 | 0.7957 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7535.092 | 0.9024 | 0.8258 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7535.092 | 0.9401 | 0.8933 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7535.092 | 0.7516 | 0.5523 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7535.092 | 0.2460 | -0.4239 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7535.092 | 0.0253 | -0.9236 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7535.092 | 0.0058 | -0.9795 | 1.1267 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7536.09 | 0.9599 | 0.9286 | 1.1257 |